CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Provisional versus elective two-stent strategy for unprotected true left main bifurcation lesions: Insights from a FAILS-2 sub-study The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis Revascularization in Patients With Left Main Coronary Artery Disease and Left Ventricular Dysfunction Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review Noninvasive Imaging for the Evaluation of Diastolic Function: Promises Fulfilled Extracellular Vesicles From Epicardial Fat Facilitate Atrial Fibrillation Single Versus Dual Antiplatelet Therapy Following TAVR: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main and Multivessel Coronary Artery Disease: Do We Have the Evidence? Coronary Access After TAVR With a Self-Expanding Bioprosthesis: Insights From Computed Tomography

Original Research2021 Mar 22.

JOURNAL:J Proteome Res. Article Link

Metabolic Interactions and Differences between Coronary Heart Disease and Diabetes Mellitus: A Pilot Study on Biomarker Determination and Pathogenesis

WP Liu, PF Guo, T Dai Keywords: diabetes coronary heart disease metabolomics metabolism

ABSTRACT

Comprehensive understanding of plasma metabotype of diabetes mellitus (DM), coronary heart disease (CHD), and especially diabetes mellitus with coronary heart disease (CHDDM) is still lacking. In this work, the plasma metabolic differences and links of DM, CHD, and CHDDM patients were investigated by the strategy of comparative metabolomics based on 1H NMR spectroscopy combined with network analysis for revealing their metabolic differences. A total of 17 metabolites are related to three diseases, among which valine, alanine, leucine, isoleucine, and N-acetyl-glycoprotein are positively correlated with CHD and CHDDM (odds ratios (OR) > 1). The trimethylamine oxide, glycerol, lactose, indoleacetate, and scyllo-inositol are closely related to the development of DM to CHDDM (OR > 1), and indoleactate (OR: 1.06, 95% confidence interval (CI): 1.01–1.12) and lactose (OR: 2.46, 95% CI: 1.67–3.25) are particularly prominent in CHDDM. We identified three multi-biomarkers types that were significantly associated with glycosylated hemoglobin (HbA1C) at baseline. All diseases demonstrated dysregulated glycolysis/gluconeogenesis and amino acid biosynthesis pathway. In addition, enrichment in tryptophan metabolism observed in CHDDM, enrichment in inositol phosphate metabolism observed in DM, and the metabolites related to microbiota metabolism were dysregulated in both DM and CHDDM. The comparative metabolomics strategy of multi-diseases offers a new perspective in disease-specific markers and pathogenic pathways.